Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.' - 2Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- 3Many European nations want Israel to cancel 19 new settlement plans
- 4Culinary Joys: Investigating Connoisseur Cooking at Home
- 5Remote Headphones: Upgrade Your Sound Insight
- Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- CVS forecasts 2026 profit above estimates on strong performance
- Partner of crime boss Steven Lyons arrested in Dubai
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- NASA will bring space station crew home early after medical issue
- Role reversal: Ukraine moves training home and exports the lessons abroad
